#GU15 - Are patients with Gleason 6 pathology safe from developing metastatic castration-resistant prostate cancer (mCRPC)? - Session Highlights

ORLANDO, FL, USA (UroToday.com) - The group from Germany investigated the association of Gleason score 6 pathology to development of metastatic castrate-resistant prostate cancer.

Patients participating in the COU-301 trial, AFFIRM trial, as well as patients with mCRPC from the group’s outpatient clinic were retrospectively evaluated. Clinical data was assessed for patients with confirmed mCRPC between 3/2007 to 10/2014.

gucancerssympaltOut of 605 screened patients, a total of 77 patients with confirmed mCRPC were identified. Distribution of Gleason scores for Gleason 6, 7, 8, 9, and 10 were 2, 24, 28, 18, and 5 patients, respectively. Pathological whole prostate specimen obtained from radical prostatectomy was available in 43/77 patients. The remainder of patients either underwent androgen deprivation therapy only, systemic therapy, or radiation therapy. None of the two patients with Gleason score 6 with mCRPC underwent radical prostatectomy. One underwent brachytherapy and another had primary ADT. The authors hypothesize likely understaging at prostate biopsy in these 2 patients with Gleason score 6. Out of the confirmed final whole prostate pathology, none had Gleason score < 7.

A total of 29 patients died during follow-up. Gleason score at initial diagnosis was not a significant prognosticator for overall survival.

The group concluded a likely non significant occurrence of mCRPC during the development of prostate cancer for patients with Gleason pathology < 7. Nonetheless, patients with Gleason score 6 on prostate biopsy still need to be counseled about the probability of under-staging.

Presented by Christoph A. J. von Klot, Alena Boeker, Thomas R. W. Herrmann, Mario W. Kramer, Markus A. Kuczyk, and Axel S. Merseburger at the 2015 Genitourinary Cancers Symposium - "Integrating Biology Into Patient-Centric Care" - February 26 - 28, 2015 - Rosen Shingle Creek - Orlando, Florida USA

Department of Urology and Urologic Oncology, Medical School Hannover, Hannover, Germany; Hannover Medical School, Hannover, Germany; Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany

Reported by Mohammed Haseebuddin, MD, medical writer for UroToday.com

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe